Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 place Henri-Dunant, 63001, Clermont-Ferrand, France; EA 4677 "ERTICA", University of Auvergne, 63011, Clermont-Ferrand, France.
Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 place Henri-Dunant, 63001, Clermont-Ferrand, France; EA 4677 "ERTICA", University of Auvergne, 63011, Clermont-Ferrand, France.
Cancer Lett. 2016 Nov 1;382(1):77-85. doi: 10.1016/j.canlet.2016.03.001. Epub 2016 Mar 7.
Triple negative breast cancer (TNBC) represents about 15% to 20% of all breast cancers and is typically associated with poorer outcome than other breast cancer subtypes. The heterogeneity of this breast cancer subtype and present lack of clinically established targeted therapies further complicates treatment of patients. The treatment of TNBC emphasizes enhancing health care and developing personalized medicine. To respond to this need, the researchers have turned their attention to a different approach to scientific enquiry: the era of "big biology" and the integrative study of biological systems, also called "Omics" technologies. The term omics comprises different fields of molecular studies and characterizes a global view on biological molecules such as DNA, RNA, proteins, and metabolites. Combined "omics" approach offers a major tool for the understanding of a challenging cancer model, TNBC. This review discusses the different discoveries made using omics technologies concerning the molecular mechanisms underlying TNBC phenotypic heterogeneity, and their potential transfer to clinical applications.
三阴性乳腺癌（TNBC）约占所有乳腺癌的 15%至 20%，与其他乳腺癌亚型相比，其预后通常更差。这种乳腺癌亚型的异质性和目前缺乏临床确定的靶向治疗方法进一步使患者的治疗复杂化。TNBC 的治疗强调增强保健和制定个性化药物。为了满足这一需求，研究人员将注意力转向了一种不同的科学研究方法：“大生物学”时代和对生物系统的综合研究，也称为“组学”技术。“组学”一词包含不同的分子研究领域，其特点是对 DNA、RNA、蛋白质和代谢物等生物分子进行全局观察。联合“组学”方法为理解具有挑战性的癌症模型 TNBC 提供了一个主要工具。这篇综述讨论了使用“组学”技术在 TNBC 表型异质性的分子机制方面所取得的不同发现，及其向临床应用的潜在转化。
